GRTXD (Galera Therapeutics) ROE % Adjusted to Book Value: -23.82% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GRTXD Galera Therapeutics Inc GRTXD
35 GF Score
Price $16.39
! 2 Warning Signs
View Full Analysis

What is Galera Therapeutics ROE % Adjusted to Book Value?

Galera Therapeutics GRTXD -1.02% 35 ROE % Adjusted to Book Value is -23.82% as of Mar. 2026. GuruFocus rates GRTXD with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Galera Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -111.01%. Galera Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 4.66. Galera Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -23.82%.

Galera Therapeutics ROE % Adjusted to Book Value Related Terms

Galera Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Galera Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galera Therapeutics ROE % Adjusted to Book Value Chart

Galera Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 Negative Equity

Galera Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 Negative Equity -23.82

GRTXD vs CELU, BCDA, KTTA: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Galera Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galera Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's ROE % Adjusted to Book Value falls into.


GRTXD
35GF Score
Galera Therapeutics Inc GRTXD
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galera Therapeutics ROE % Adjusted to Book Value Calculation

Galera Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / 0.42
=Negative Equity

Galera Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-111.01% / 4.66
=-23.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -23.82% mean?
Galera Therapeutics (GRTXD) has a ROE % Adjusted to Book Value of -23.82% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Galera Therapeutics and its competitors.
Is Galera Therapeutics' ROE % Adjusted to Book Value too high?
Galera Therapeutics' current ROE % Adjusted to Book Value is -23.82%. Overall, Galera Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Galera Therapeutics' ROE % Adjusted to Book Value compare to CELU and BCDA?
Galera Therapeutics' ROE % Adjusted to Book Value of -23.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Galera Therapeutics and its competitors. Galera Therapeutics's current ROE % Adjusted to Book Value is -23.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galera Therapeutics stock overvalued right now?
Galera Therapeutics (GRTXD) has a current ROE % Adjusted to Book Value of -23.82%. The current ROE % Adjusted to Book Value is -23.82%. Galera Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Galera Therapeutics (GRTXD), the current ROE % Adjusted to Book Value is -23.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galera Therapeutics Business Description

Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Galera Therapeutics Inc is a biopharmaceutical company that historically was focused on developing a portfolio of small-molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, mainly by reducing one of the common side effects of radiotherapy, severe oral mucositis (SOM). Superoxide Dismutase Mimetics: excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galera's SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advance breast cancer. Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion.
35GF Score

Get the complete analysis for GRTXD

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.39
Price